Randall Henri Steinmeyer,

Name a company with married C Suite executives and the company is not a major fraud. ( I have never seen one ) $BNTX

Name a time officers bought into or immediately after IPO and it was not a fraud. Go! $PICS

@jevgenijs Long?

PicPay $PICS financials (nine months of 2025): ✔️ Net revenue from transaction activities: 18% ✔️ Financial income: 82%

$PICS IPO hype: ‘Favorable unit economics’ + ‘strict credit criteria.’ Weeks later BRL 88M provision shock, Stage 3 reclass, 22% drop. CFO: ‘We had more information about portfolio performance…’ Now hovering ~$11 with slashed targets. Fraud!

A comparison of the similarities between the Sri Yantra Mandala and a Tonoscope picture of the sound OM. Probably just a coincidence.

$BATL said the problem was basically fixed. Then disclosed: 4,300 BOE/D curtailed all quarter That’s ~38% of production. Then: execs sold to zero insiders dumped millions directors resigned Not recovery. Exit liquidity

Some things never change. #Artemis #Moon

@OldWorldPlans Amazing

An incredible drawing of an incredible piece of architecture—St. Paul's Cathedral in London. Completed in 1672-1710 by Christopher Wren, drawing by Colen Campbell.

@lazereater $83M in incremental SG&A is not "safety," it's the cost of keeping the story intact. (-50% in past 30 days )

(1) Have you considered the margin of Safety for $TPB? Prior to the launch of nicotine pouches, from Q1 of 22 to Q4 of 23, SG&A averaged $26MM a quarter. In Q4 of 25 SG&A was $46.8MM. On an anulized basis, that is an increase of $83MM to grow the nicotine pouch business.

Sea lions surfing huge waves near Santa Barbara Island, California filmed by Ryan Lawler of Pacific Offshore Expeditions

@AndrewTakes @lazereater Bruh: Look at past Q statements: "Balanced growth" "Favorable out of the gates" But: slotting up contra-revenue up spend per can up So, if unit economics improve, spend per unit drops vs spikes up. This why -50%

@lazereater @Randall7575 Invert man, judging by the writing style of Randall's responses, it looks like an LLM is writing those for him. Wouldn't give him the time of day.

$TPB 7-Eleven shelf ≠ demand. If it takes slotting fees + discounts to move cans, that’s not growth—it’s bought velocity.

@Rebel94289165 @lazereater Bru: You’re arguing labels—I’m looking at the math. If volume is up but net revenue per can isn’t, something is offsetting it. Call it what you want—the economics don’t lie. Also, since -50% in 4 weeks, is market wrong too?

@Randall7575 @lazereater They are not discounting what are you taking about. Short of course. They are the least promotional of any of the brands.

@lazereater $CELH paid for access once—then demand took over. If $TPB still needs to pay + discount to drive volume, that’s the difference.

@Randall7575 Do you think that was the same case with $CELH? It pays 20-30% of revs in slotting fees. You need to do some homework. You are not alone though. That is what creates the opertunity in $TPB's stock today.

@lazereater @CondensedI Slotting fees don’t fix this — they are the issue. $TPB sold ‘improving economics,’ not ‘we’re buying distribution.’ If growth requires incentives that compress margins, that’s not strength — that’s subsidized volume

@Randall7575 @CondensedI You obviously do not understand the convienience store channel. You have to pay slotting fees to have access to the back bar in large chanins like 7 Eleven or Circle K. Management signaled that they would be making more investents to have access in Q3.

$TPB story: “Growth is balanced. Profits improving.” Actual math: Revenue ↑ 29% Modern Oral ↑ 266% EBITDA ↓ 10–20% Then they guided it lower Stock −20% You weren’t early. You were misled.

$LPCN didn’t just run a risky biotech trial — they de-risked it for you. • “Encouraging progress” • “Promising” safety • Bioequivalent to Zulresso • Raised cash Reality: efficacy was a binary coin flip That’s manufactured visibility into an unknowable outcome.

Aviat didn’t grow — it pulled forward cash and called it growth. Revenue up. EBITDA up. Cash? Trapped in working capital. When the timing unwinds, so does the story. $AVNW

@lazereater @CondensedI Back out contra-revenue’ = ignore the discounts driving growth. $TPB pitched improving economics, not just volume. If demand were real, you wouldn’t need incentives. Volume ≠ profitability.

@CondensedI @Randall7575 When you back out contra revenue las quarter for $tpb’s nicotine pouches was not soft. The only thing that matters is how many nicotine pouch cans are ultimately purchased by the end consumer without material discounts.

If a company says: “we have visibility” …and misses EPS by ~30% three months later You don’t have a forecasting issue. You have a truth issue. $LNN

AI capex pause in motion. $NVDA

$ORIC sold stock off “compelling” data that supposedly supported best-in-class positioning. Weeks later: Phase 3 dose chosen for safety — not superiority. That’s not biotech risk. That’s disclosure risk.